Oral Nutritional Supplement in Type 2 Diabetes Subjects With or at Risk of Malnutrition

Inclusion Criteria:

• Type 2 diabetes on treatment with one or more oral antidiabetics/insulin andconstant dose for at least 2 months

• Has HbA1c < 9.0% based on recent (30 days prior to Baseline visit) laboratory valueor analysis of blood sample obtained at Baseline Visit

• Adult population with age ≥30 years

• Willing to follow the protocol as described

• Voluntarily signed and dated an informed consent form (ICF), approved by anIndependent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to anyparticipation in the study to allow their data to be collected

• Subject is under the care of a health care professional for malnutrition, or is atrisk for malnutrition (MUST≥1), and has recently (within the last 7 days prior toparticipating in this study) been prescribed study oral nutritional supplement (2servings/day) by their health care professional

Exclusion Criteria:

• History of T2D longer than 30 years

• History of diabetic ketoacidosis and or hyperosmolar hyperglycemic state (HHS)

• If on thyroid medication or hormone replacement therapy, has not been on a constantdosage for at least 2 months prior to Baseline Visit

• History of metabolic/endocrine (other than diabetes), hepatic (AST/ALT 3 times theupper normal limit), or significant renal disease (GFR < 60 ml/min/1.73m2)

• History of heart failure (> class II)

• Follows a non-typical eating pattern, such as very low carbohydrate diet (e.g.,Atkins diet, ketogenic diet, high protein diet), strict vegetarianism (e.g., nomeat, dairy, eggs).

• Is pregnant as confirmed via urine pregnancy test, attempting to conceive or notwilling and able to practice birth control during the study duration

• Has current infection (requiring medication or which might be expected to requirehospitalization); has had inpatient surgery, or corticosteroid treatment (excludingtopical creams) in the last 3 months or antibiotics in the last 3 weeks prior toBaseline Visit.

• Has an active malignancy

• Known to be allergic or intolerant to any ingredient found in the study products

• Taking any medications, herbals, or dietary supplements, other than allowedmedications, during the past 4 weeks that could profoundly affect (in the opinion ofthe PI or study physician) blood glucose or appetite modifying medications (examplesinclude orlistat, contrive, incretins, cannabis).

• Has known dementia, eating disorders, history of significant neurological orpsychiatric disorder, or any other psychological condition that may interfere withstudy product consumption AND does not have a caregiver who can assist them withadherence to the study protocol

• Participant in a concomitant AN trial or trial of a nonregistered drug (or is withinthe 30 days follow-up period for such a trial) or that otherwise conflicts with thisstudy unless otherwise approved by Abbott Nutrition.

• Patient is receiving any other oral supplement with HMB for nutritional managementin the last 7 days